Hypertrophic cardiomyopathy (HCM) affects 1 in 200-500 people and leads to hyper-contractility of the ventricles of the heart. HCM is the leading cause of sudden death in young adults, often taking an insidious clinical course. Early detection may be beneficial for prevention of significant morbidity and mortality in high‐risk patients, and specialty-specific tools to aid in that early diagnosis are needed. Unfortunately, the clinical and genetic complexity of HCM and its manifold molecular mechanisms have hindered the development of effective treatment options. Directly manipulating the power output of cardiac muscle at the molecular level via a targeted small-molecule inhibitor of myosin would abrogate the elevated contractile force of the HCM heart and potentially improve symptoms and alter the course of disease progression. A signal advance in the management of HCM has been achieved with the first regulatory approval of such a myosin inhibitor. We have now entered a new era of HCM management, and our global expert faculty in this program will educate learners on the pathophysiology of the disease, the latest diagnostic imaging techniques, and optimal treatment as per the 2023 ESC Cardiomyopathy Management Guidelines.
Cardiologists, electrophysiologists, heart failure specialists, and other healthcare professionals involved in the management of patients with HCM
An improved understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM
Improved confidence and competence in diagnostic skill for recognizing HCM
A clear understanding of the differences between symptom management and pathophysiology-targeted treatment for patients with HCM
Practice-pertinent awareness of the most recent clinical data on the efficacy and safety of CMIs in the management of HCM
Familiarity with the most current specialty society guidelines addressing the management of HCM
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Eugene Braunwald, MD | Consultant/Advisor: Amgen Inc.; Bristol Myers Squibb; Boehringer Ingelheim; Cardurion Pharmaceuticals; Lilly; Verve Therapeutics, Inc. Grant/Research Support: AstraZeneca; Daiichi Sankyo Company, Limited; Merck & Co., Inc.; Novartis AG |
| Thor Edvardsen, MD, PhD | Nothing to disclose |
| Iacopo Olivotto, MD | Consultant/Advisor: Amicus Therapeutics, Inc.; Cytokinetics; Genzyme; Rocket Pharmaceuticals, Inc.; Shire/Takeda Pharmaceutical Company; Tenaya |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Learners should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from Bristol Myers Squibb.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
